Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Items 301–400 of 780
Yan, L., Zhu, M., Wang, D., Tao, W., Liu, D., Zhang, F., Linhardt, R. J., Ye, X., & Chen, S. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1714738 · Cited by 20
Feng, W., Wang, X., Huang, D. F., & Lu, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105438 · Cited by 20
Chen, J., Lv, M., Wu, S., Jiang, S., Xu, W., Qian, J., Chen, M., Fang, Z., Zeng, Z., & Zhang, J. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.10.054 · Cited by 21
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Boyd, R., DiCarlo, L. A., & Mandema, J. W. (2017) · Clinical and Translational Science · doi:10.1111/cts.12471 · Cited by 20
Li, A., Zhang, M. C., Li, P., Eshaghpour, A., Li, K. T., Carrier, M., Wells, P. S., & Crowther, M. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.003 · Cited by 18
Mandavia, R., Shalhoub, J., Head, K., & Davies, A. H. (2014) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2014.10.002 · Cited by 21
Use of direct oral anticoagulants with regional anesthesia in orthopedic patients
Cappelleri, G., & Fanelli, A. (2016) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2016.02.028 · Cited by 21
Myers, J. A., Wittenburg, L. A., Olver, C. S., Martinez, C. M., & Bright, J. M. (2015) · American Journal of Veterinary Research · doi:10.2460/ajvr.76.8.732 · Cited by 18
Turpie, A. G. G. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712453067 · Cited by 20
“…the results of several successful phase III studies in the prevention and treatment of thromboembolic disorders [Connolly et al. 2009; Eriksson et al. 2007a, 2007b, 2008; Kakkar et al. 2008; Lassen et al. 2008, 2010a, 2010b; Patel et al. 2011; The EINSTEIN Investigators, 2010; Turpie et al. 2009].”
BackgroundCaldeira, D., Rodrigues, F. B., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2017) · Clinical Medicine Insights Blood Disorders · doi:10.1177/1179545x17704660 · Cited by 18
Shah, R., Sheikh, N., Mangwani, J., Morgan, N. J., & Khairandish, H. (2020) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2020.08.005 · Cited by 19
Spénard, E., Geerts, W. H., Lin, Y., Gien, L. T., Kupets, R., Covens, A., & Vicus, D. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.02.012 · Cited by 18
Rich, J. M., Elkun, Y., Geduldig, J. E., Lavallée, É., Mehrazin, R., Attalla, K., Wiklund, P. N., & Sfakianos, J. P. (2023) · British Journal of Urology · doi:10.1111/bju.16036 · Cited by 19
“Similar results were found following total hip replacement, with a 35-day trial of apixaban for VTE thromboprophylaxis providing an absolute risk reduction of 2.5% compared to enoxaparin [17].”
InfluentialMaratea, D., Fadda, V., Trippoli, S., & Messori, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04421.x · Cited by 18
Prevention of VTE in orthopedic surgery patients
Spandonaro, F., Mancusi, R. L., Terranova, L., Giannarelli, D., Grossi, P., Imberti, D., & Mazza, E. L. (2013) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v14i2s.881 · Cited by 17
Newer Oral Anticoagulant Agents: A New Era in Medicine
Goel, R., & Srivathsan, K. S. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801784934 · Cited by 21
“The enoxaparin was started 12 hours preoperatively and the apixaban started 12-24 hours post-operatively in both groups [32, 33].”
MethodThe emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review
Pinto, D. J. P., Qiao, J. X., & Knabb, R. M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.680438 · Cited by 17
“Apixaban was also investigated for prevention of VTE after orthopedic surgery [30-32].”
BackgroundFrost, C. E., Merali, S. J., Shenker, A., Barrett, Y. C., & LaCreta, F. P. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.990 · Cited by 19
Direct oral anticoagulants: a guide for daily practice
Fontana, P., Robert‐Ebadi, H., Bounameaux, H., Boehlen, F., & Righini, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14286 · Cited by 22
Blin, P., Samama, C. M., Sautet, A., Bénichou, J., Lignot-Maleyran, S., Lamarque, S., Lorrain, S., Lassalle, R., Droz‐Perroteau, C., Mismetti, P., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.018 · Cited by 20
Ding, K., Yan, W., Zhang, Y., Li, J., Li, C., & Liang, C. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.02.113 · Cited by 18
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 18
Should patients with systemic sclerosis‐related pulmonary arterial hypertension be anticoagulated?
Nikpour, M., Stevens, W., Proudman, S., Buchbinder, R., Prior, D., Zochling, J., Williams, T., Gabbay, E., & Nandurkar, H. H. (2013) · Internal Medicine Journal · doi:10.1111/imj.12111 · Cited by 16
Dosing of Target-Specific Oral Anticoagulants in Special Populations
Morrill, A. M., Ge, D., & Willett, K. C. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015591846 · Cited by 16
Yan, X., Gu, X., Xu, Z., Lin, H., & Wu, B. Y. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0460-0 · Cited by 16
“Hazard ratio of rivaroxaban versus enoxaparin [18, 19]”
MethodRahmanzade, R., Cabrera-Diaz, F., Zaugg, C., Schüetz, P., & Salili, A. R. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00227-w · Cited by 17
“It has been attributed to the concomitant polymorbidity and polypharmacy of patients with venous thromboembolic disorders [33, 34].”
BackgroundWinchester, C. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s26482 · Cited by 17
“The ADVANCE-2 and ADVANCE-3 trials in TKR and THR surgery demonstrated that apixaban is more effective than the enoxaparin regimen for the primary efficacy outcome (asymptomatic and symptomatic deep vein thrombosis, nonfatal pulmonary embolism, and all-cause death), with no significant difference in the rate of major…”
BackgroundTiming the First Postoperative Dose of Anticoagulants
Paikin, J. S., Hirsh, J., Chan, N., Ginsberg, J. S., Weitz, J. I., & Eikelboom, J. W. (2015) · CHEST Journal · doi:10.1378/chest.14-2710 · Cited by 16
The Role of Apixaban for Venous and Arterial Thromboembolic Disease
Prom, R., & Spinler, S. A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q119 · Cited by 21
How we treat bleeding associated with direct oral anticoagulants.
Marano, G., Vaglio, S., Pupella, S., Liumbruno, G. M., & Franchini, M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2016.0180-15 · Cited by 18
The role of new oral anticoagulants in orthopaedics: an update of recent evidence
Papadopoulos, D. V., Kostas‐Agnantis, I., Gkiatas, I. S., Tsantes, A. G., Ziara, P., & Korompilias, A. V. (2017) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-017-1940-x · Cited by 16
Udayachalerm, S., Rattanasiri, S., Angkananard, T., Attia, J., Sansanayudh, N., & Thakkinstian, A. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618796339 · Cited by 16
“Factor Xa inhibitors are also indicated for thromboprophylaxis in orthopedic surgery.(7-9) Many advantages of these drugs are claimed over warfarin including less drug interactions, rapid onset of action without initial parenteral anticoagulation, fixed once or twice daily dose without the need for frequent monitoring…”
BackgroundKwok, C. S., Pradhan, S., Yeong, J. K.-Y., & Loke, Y. K. (2013) · CHEST Journal · doi:10.1378/chest.12-2634 · Cited by 17
Should deep venous thrombosis prophylaxis be used in fast-track hip and knee replacement?
Kjærsgaard‐Andersen, P., & Kehlet, H. (2012) · Acta Orthopaedica · doi:10.3109/17453674.2012.672094 · Cited by 18
Novel Anticoagulants for Atrial Fibrillation: A Critical Appraisal
Tzeis, S. E., & Andrikopoulos, G. K. (2011) · Angiology · doi:10.1177/0003319711422808 · Cited by 17
Cheok, T. S., Beveridge, A., Berman, M., Coia, M., Campbell, A., Tse, T. T. S., Doornberg, J. N., & Jaarsma, R. L. (2024) · The Bone & Joint Journal · doi:10.1302/0301-620x.106b9.bjj-2023-1252.r2 · Cited by 15
Guasti, L., Fumagalli, S., Afilalo, J., Geisler, T., Abreu, A., Ambrosetti, M., Gevaert, S., Christodorescu, R., Richter, D. J., Aboyans, V., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf010 · Cited by 17
Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials
Friedman, R. J. (2011) · Orthopedics · doi:10.3928/01477447-20110826-24 · Cited by 16
Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors
Shi, Y., O’Connor, S. P., Sitkoff, D. F., Zhang, J., Shi, M., Bisaha, S. N., Wang, Y., Li, C., Ruan, Z., Lawrence, R. M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.098 · Cited by 16
Green, B., Mendes, R. A., der Valk, R. V., & Brennan, P. A. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12441 · Cited by 15
Zufferey, P. J., Ollier, É., Delavenne, X., Laporte, S., Mismetti, P., & Duffull, S. B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13663 · Cited by 15
Bala, A., Murasko, M. J., Burk, D. R., Huddleston, J. I., Goodman, S. B., Maloney, W. J., & Amanatullah, D. F. (2019) · Hip International · doi:10.1177/1120700019841600 · Cited by 16
Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery
Siscos, S. M., Neill, B. C., Singh, A. H., & Hocker, T. L. H. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.10.008 · Cited by 15
Jamieson, M. J., Byon, W., Dettloff, R. W., Crawford, M., Gargalovic, P. S., Merali, S. J., Onorato, J. M., Quintero, A., & Russ, C. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00524-x · Cited by 16
“5 mg bid with enoxaparin 40 mg QD subcutaneously for prevention of DVT, PE, or all-cause death in patients undergoing total knee (ADVANCE-2) or hip (ADVANCE-3) replacement [71, 72].”
MethodRole of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
Tun, H. N., Kyaw, M. T., Rafflenbeul, E., & Suástegui, X. L. (2022) · European Cardiology Review · doi:10.15420/ecr.2021.55 · Cited by 21
Efficacy and safety of novel anticoagulants compared with established agents
Rybak, I., Ehle, M., Buckley, L. F., & Fanikos, J. R. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711408489 · Cited by 15
“ADVANCE-1, ADVANCE-2, and ADVANCE-3 were double-blind clinical trials evaluating apixaban for VTE prophylaxis in orthopedic surgery patients [Lassen et al. 2010a, 2010b, 2009] (Table 5).”
BackgroundInfluentialShantsila, E., & Lip, G. Y. H. (2010) · doi:10.1007/978-1-908517-08-1_5 · Cited by 15
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
VTE primary prevention, including hospitalised medical and orthopaedic surgical patients
Granziera, S., & Cohen, A. T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0823 · Cited by 20
Godiér, A., Lasne, D., Pernod, G., Blais, N., Bonhomme, F., Bounes, F. V., Bourguignon, A., Cohen, A. A., de Maistre, E., Fontana, P., et al. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101446 · Cited by 18
Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease.
Budovich, A., Zargarova, O., & Nogid, A. (2013) · Europe PMC (PubMed Central) · Cited by 20
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2014) · Cited by 15
Johnston, S. (2015) · Dental Update · doi:10.12968/denu.2015.42.9.840 · Cited by 16
Pharmacologic prevention of venous thromboembolism in obese patients
Bakirhan, K., & Strakhan, M. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0844-1 · Cited by 14
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism
den Exter, P. L., Kooiman, J., van der Hulle, T., & Huisman, M. V. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.004 · Cited by 14
Tun, N. M., & Oo, T. H. (2013) · Thrombosis · doi:10.1155/2013/183616 · Cited by 16
“5mg twice daily) showed superior efficacy compared to enoxaparin (40mg daily) [65, 66].”
BackgroundPractical management of new oral anticoagulants after total hip or total knee arthroplasty
Klauser, W., & Dütsch, M. (2013) · MUSCULOSKELETAL SURGERY · doi:10.1007/s12306-013-0306-8 · Cited by 15
New options in anticoagulation for the prevention of venous thromboembolism and stroke.
Clayville, L. R., Anderson, K. V., Sa, M., & Onge, E. S. (2011) · PubMed · Cited by 14
The Prevention of Venous Thromboembolism in Surgical Patients
Hansrani, V., Khanbhai, M., & McCollum, C. N. (2016) · Advances in experimental medicine and biology · doi:10.1007/13780_2016_24 · Cited by 15
Management of Bleeding Complications in the Anticoagulated Patient
Bhagirath, V. C., O’Malley, L., & Crowther, M. A. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2011.08.008 · Cited by 14
Management of heparin-induced thrombocytopenia
Jaax, M. E., & Greinacher, A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.678834 · Cited by 16
“(2012) 13(7) Iprivask , Canyon Pharmaceutics, Switzerland) is still available in Europe and the US; and in several developing countries, hirudin rb variant (Thrombexx, Rhein-Minapharm, Egypt).”
BackgroundInfluentialHumphrey, T. J., O'Brien, T., Melnic, C. M., Verrier, K. I., Chen, A. F., Ahmed, K. F., & Bedair, H. S. (2022) · The Journal of Arthroplasty · doi:10.1016/j.arth.2022.01.089 · Cited by 13
Chapelle, C., Bertoletti, L., Lega, J., Cucherat, M., Zufferey, P. J., Darmon, J., Mismetti, P., Laporte, S., & the META-EMBOL Group (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-01-0064 · Cited by 15
New oral anticoagulants – a review
Ghanima, W., Atar, D., & Sandset, P. M. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.1111 · Cited by 18
“Apixaban was non-inferior to enoxaparin 40 mg 1 (7, 8), but was inferior to enoxaparin 30 mg 2 daily (6).”
BackgroundBreakthroughs in Anticoagulation: Advent of the Oral Direct Factor Xa Inhibitors
Augoustides, J. G. (2012) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2012.03.029 · Cited by 14
Helin, T., Virtanen, L., Manninen, M. J., Leskinen, J., Leppilahti, J. I., Joutsi‐Korhonen, L., & Lassila, R. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1492-2 · Cited by 13
“The dosages for this indication are 2.5 mg BID for apixaban and 10 mg OD for rivaroxaban, and they have been reported to be superior to enoxaparin for thromboprophylaxis after THA [1, 2].”
BackgroundInfluentialBrincat, A., & Azzopardi, L. M. (2013) · OAR@UM (University of Malta) · Cited by 13
Venous thromboembolism: identifying patients at risk and establishing prophylaxis
Shirvanian, S., & Tapson, V. F. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1098599 · Cited by 14
Agarwal, A. R., Ahmed, A. F., Stadecker, M. J., Miller, A. S., Best, M. J., & Srikumaran, U. (2023) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-22-00825 · Cited by 12
Özler, T., Uluçay, Ç., Önal, A., & Altıntaş, F. (2015) · Acta Orthopaedica et Traumatologica Turcica · doi:10.3944/aott.2015.14.0219 · Cited by 12
Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery
D’Astous, J., Liederman, Z., & Douketis, J. D. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1891751 · Cited by 15
Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery
Alsheikh, K., Hilabi, A. S., Aleid, A., Alharbi, K. G., Alangari, H. S., Alkhamis, M., Alzahrani, F., & Almadani, W. H. (2021) · Cureus · doi:10.7759/cureus.19691 · Cited by 16
“Oral direct factor Xa inhibitors including rivaroxaban, dabigatran, and apixaban have the same VTE events compared with patients taking LMWH in orthopedic surgery [15-22].”
BackgroundHirsh, J., Ginsberg, J. S., Chan, N., Guyatt, G. H., & Eikelboom, J. W. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-07-0562 · Cited by 14
“Despite differences in the incidence of asymptomatic venographic thrombosis in contemporary clinical trials in elective major orthopaedic surgery comparing newer anticoagulants with enoxaparin (18-28), the post-operative mortality, assessed at the time of venography is very low and similar among groups (▶ Table 2).”
BackgroundSBA Recommendations for regional anesthesia safety in patients taking anticoagulants
Fonseca, N. M., de Anestesiologia, S. B., Alves, R. R., & Pontes, J. P. J. (2013) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2013.04.010 · Cited by 19
Oral and parenteral anticoagulants: New kids on the block
Aditya, S. (2012) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.105448 · Cited by 12
Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty
Flierl, M. A., Messina, M. J., Mitchell, J. J., Hogan, C. A., & D'Ambrosia, R. D. (2015) · Orthopedics · doi:10.3928/01477447-20150402-06 · Cited by 11
Abdelsalam, H., Sakr, M. A. S., Saroka, V. A., Abdelrazek, G. M., Abd-Elkader, O. H., Teleb, N. H., Liu, Y., & Zhang, Q. (2024) · Materials Science and Engineering B · doi:10.1016/j.mseb.2024.117327 · Cited by 11
Liang, J. Q., Bergqvist, D., Yusen, R. D., & Hull, R. D. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-08-0654 · Cited by 11
Carter, K. L., Streiff, M. B., Ross, P. A., Wellman, J. C., Thomas, M. L., Kraus, P. S., & Shermock, K. M. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0781-z · Cited by 11
The novel anticoagulants: The surgeons' prospective
Shamoun, F. E., Martin, E. N., & Money, S. R. (2012) · Surgery · doi:10.1016/j.surg.2012.09.016 · Cited by 11
Pathak, R., Giri, S., Karmacharya, P., Aryal, M. R., Poudel, D. R., Ghimire, S., Jehangir, A., Shaikh, B. F., Rettew, A., & Donato, A. A. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000369 · Cited by 12
Liu, F., Chu, X., Huang, J., Tian, K., Hua, J., & Tong, P. (2014) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-014-1939-2 · Cited by 11
Thromboprophylaxis in urological surgery
Tikkinen, K. A. O., Cartwright, R., Gould, M. K., Naspro, R. L., Novara, G., Sandset, P. M., Violette, P. D., & Guyatt, G. H. (2018) · Cited by 12
Wang, Y., Xu, X., & Wei, Z. (2024) · Journal of orthopaedic surgery · doi:10.1177/10225536241233473 · Cited by 13
A Systematic Review and Adjusted Indirect Comparison of Oral Anticoagulants
Cui, J., Wu, B., Liu, C., & Li, Z. (2014) · Orthopedics · doi:10.3928/01477447-20141023-07 · Cited by 11
Thromboembolism in Orthopedic Surgery
Llau, J. V. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4336-9 · Cited by 10
Buck, M. M., Haddon, A. M., Paneccasio, A., Skoloda, D., Zimmerman, D. E., Guarascio, A. J., Nemecek, B. D., Covvey, J. R., & Montepara, C. A. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01019-4 · Cited by 11
“These analyses were derived from the following trials: COMPASS [35], ROCKET AF [1], ARISTOTLE [2], EINSTEIN DVT [36] and PE [37], ADVANCE-2 [38] and -3 [39], XAPASS [40], and ARISTOPHANES [41].”
MethodYamada, N., Mo, M., Ohsawa, A., Sato, M., Umeyama, M., Shima, D., & Nakamura, M. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-0829 · Cited by 14
Knisely, A. T., Iniesta, M. D., Batman, S. H., Meyer, L. A., Soliman, P. T., Cain, K. E., Marten, C. A., Chisholm, G. B., Schmeler, K. M., Taylor, J. S., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.01.039 · Cited by 11
Berndtson, A. E., Cross, A. M., Yorkgitis, B. K., Kennedy, R., Kochuba, M. P., Tignanelli, C. J., Tominaga, G. T., Jacobs, D. G., Ashley, D. W., Ley, E. J., et al. (2024) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000004307 · Cited by 13
Dharmarajan, T. S., Nanda, A., Agarwal, B., Agnihotri, P., Doxsie, G., Gokula, M. R., Javaheri, A., Kanagala, M., Lebelt, A. S., Madireddy, P., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.04.015 · Cited by 10
Oo, T. H., & Zalpour, A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s51006 · Cited by 10
Consenso SECOT sobre tromboembolismo en la cirugía protésica de rodilla y cadera
Castellet, E., Peidro, L., & Otero, R. (2013) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2013.01.003 · Cited by 12
Yu, Z. J., Shan, P., Yang, X., & Lou, X.-J. (2018) · Bioscience Reports · doi:10.1042/bsr20180423 · Cited by 10
Johnson, S. A., Jones, A. E., Young, E. W., Jennings, C., Simon, K., Fleming, R. P., & Witt, D. M. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.08.009 · Cited by 10
Direct Oral Anticoagulants: A Review for the Non-Specialist
Gunawardena, T. (2021) · Hematology Reports · doi:10.4081/hr.2021.9239 · Cited by 10
Pinto, D. J. P., Wong, P. C., Knabb, R. M., & Wexler, R. R. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00009-6 · Cited by 11
Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials
Tornyos, A., Vorobcsuk, A., Kupó, P., Aradi, D., Kehl, D., & Komócsi, A. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1096-z · Cited by 10
“Three studies included patients who required total knee replacement and one included hip replacement [7, 9, 10, 18].”
Thromboprophylaxis in major knee and hip replacement surgery: a review
Gonzalo Eymin, L., & Jaffer, A. K. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0751-5 · Cited by 10
“ADVANCE2 [37] 3,057 TKR Apixaban at 2.”
Background
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.